Is it possible to refine the indication for sentinel node biopsy in high-risk ductal carcinoma in situ?

Abstract

The relevance of SNB positivity cannot be overlooked in high-risk DCIS patients, however, because SNB is not free from morbidity and cost, more studies are needed to refine its final indication.

Meta-analysis of sentinel node biopsy in ductal carcinomain situof the breast

“…Reference Klauber-DeMore et al 29 Pendas et al 19 Mittendorf et al 31 Camp et al 32 Yen et al 33 Takacs et al 34 Fraile et al 35 Moran et al 36 Meijnen et al 37 Moore et al 38 Cox et al 18 For example, some reports doubled their node positivity frequencies by using immunohistochemistry to detect SLN involvement 14,18,30 . The differences in the reported frequencies of nodal metastases may also reflect the patient populations studied.…”

The Impact of Sentinel Lymph Node Biopsy and Magnetic Resonance Imaging on Important Outcomes Among Patients With Ductal Carcinoma In Situ

“…Some studies evaluating the role of SLN biopsy include DCISM, whereas others include only pure DCIS without microinvasion. Because DCISM may have a higher incidence of SLN metastases, we distinguished DCIS from DCISM in our analysis (5,(7)(8)(9)(10)(11)(12)(13)15,17,(19)(20)(21)(22)(23)(24)(25)(27)(28)(29)(30)(31)(33)(34)(35). The incidence of SLN metastases was higher for patients with DCISM (9.3%; 95% CI = 6.0% to 14.0%) as compared with those with DCIS (4.8%; 95% CI = 3.4% to 6.7%).…”